Regentis Biomaterials Ltd. (NYSE American: RGNT) is making strides in orthopedic medicine with its lead product, GelrinC, a cell-free hydrogel implant designed to repair knee cartilage damage through a single, approximately 10-minute procedure. The company is positioning itself to address a significant unmet need: roughly 472,500 arthroscopic knee procedures in the U.S. each year involve cartilage damage, yet no approved off-the-shelf regenerative solution capable of restoring hyaline-like cartilage currently exists in the U.S. market.
Unlike traditional microfracture procedures or complex cell-based therapies that often require multiple surgeries and lengthy preparation, GelrinC is designed as a ready-to-use implant that supports native cartilage regeneration over time. The product has already received CE Mark approval in Europe and is advancing through a pivotal U.S. FDA trial that is now more than 50% enrolled. Regentis is also preparing for potential commercialization, highlighted by a newly patented solvent-free manufacturing process that increased production yield by 400%, alongside ongoing efforts to build physician adoption infrastructure across Europe.
Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis’ Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. GelrinC aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.
To view the full article, visit https://ibn.fm/TrCv1. For more information about Regentis Biomaterials, the latest news and updates relating to RGNT are available in the company’s newsroom at https://ibn.fm/RGNT.
